Peer-reviewed veterinary case report
New antibody developed to treat canine lymphoma targeting CD20
By T. Mizuno et al.·Published in Scientific Reports·2020·View original on Semantic Scholar →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Generation of a canine anti-canine CD20 antibody for canine lymphoma treatment
- Species:
- dog
Plain-English summary
A study developed a new treatment for dogs with lymphoma, a common type of cancer in pets. Researchers created an antibody specifically designed to target canine lymphoma cells, which showed promising results in lab tests by effectively killing these cancer cells. The new antibody, called 4E1-7-B_f, was found to be particularly effective, showing ten times more activity than its predecessor. This treatment could potentially improve outcomes for dogs with lymphoma, which currently have a low survival rate with existing therapies. Further testing is needed, but this could be a hopeful option for affected dogs in the future.
People also search for: dog lymphoma treatment · canine cancer antibody · beagle lymphoma survival rate
Abstract
Lymphoma is the most common hematological cancer in dogs. Canine diffuse large B cell lymphoma shows a relatively good response to treatment with multi-agent cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy; however, the 2-year survival rate is as low as 20%. For human B cell type lymphoma, the anti-CD20 chimeric antibody, rituximab, was developed two decades ago. The combination of rituximab and CHOP chemotherapy was highly successful in improving patient prognosis. However, no anti-canine CD20 antibody is available for the treatment of canine lymphoma. During this study, a rat anti-canine CD20 monoclonal antibody was established. We also generated a rat-canine chimeric antibody against canine CD20 designed for clinical application. This chimeric antibody (4E1-7-B) showed in vitro antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against the canine B cell lymphoma cell line CLBL-1. Moreover, to obtain stronger ADCC activity, a defucosylated 4E1-7-B antibody (4E1-7-B_f) was also generated, and it showed tenfold stronger ADCC activity compared with 4E1-7-B. 4E1-7-B_f as well as 4E1-7-B suppressed the growth of CLBL-1 tumors in an immunodeficient xenotransplant mouse model. Finally, a single administration of 4E1-7-B_f induced considerable peripheral B cell depletion in healthy beagles. Thus, 4E1-7-B_f is a good antibody drug candidate for canine B cell type lymphoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Semantic Scholar: https://www.semanticscholar.org/paper/7c829a6cdc38ab291985be99c5c24a6cefe62df5